Abstract Background/Aims Obesity impacts psoriatic disease (PsD) particularly regarding disease onset, disease severity and treatment non-response. The new weight-loss agents, such as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) have potential benefits for PsD disease activity and related co-morbidities but come with significant cost. We were therefore keen to explore rheumatologists and dermatologists’ opinions on the potential role of these drugs in the management of PsD. Methods We conducted an online survey of rheumatology and dermatology colleagues between the 7th April and 22nd of September 2025. Questions were developed through expert consensus and covered speciality, job role, region of practice, clinical setting, the impact of excess weight on disease and treatment response, and the monitoring and management of adiposity in PsD. Target health professionals included consultants, speciality doctors, registrars, research fellows, physiotherapists, and nurse specialists. The survey was disseminated ad hoc via professional and institutional mailing lists. Although originally meant for UK-based clinicians, the survey was later opened to international colleagues. Results were analysed with descriptive statistics. Results We received 190 responses, 150 from the UK (79%), with rheumatology contributing 131 (69%) and dermatology 59 (31%). Most respondents were consultants (68%) working in academic units/teaching hospitals (64%). Only 25% of respondents measured weight and BMI at every clinic visit, despite the majority believing that excess adiposity decreases treatment response to csDMARDs (73%) and ts/bDMARDs (75%), increases inflammatory drive and/or disease activity (87%), and is associated with cardiovascular/diabetic comorbidities (93%). Overall, 62% of respondents said that they consistently address excess adiposity in their patients, mainly through weight loss advice (92%) or weight management referral (47%). Barriers to addressing excess adiposity included time pressures, a lack of expertise and a lack of local services. Respondents were more favourable towards a hypocaloric diet over a GLP-1RA for the management of PsD in those living with overweight or obesity, including before PsA-onset in high-risk patients (35% vs 27%), before initiating systemic DMARD (52% vs 27%) or alongside the prescription of a systemic DMARD (46% vs 36%). Opinions around GLP-1-RA therapy were generally positive, with the caveat that further evidence of their efficacy and safety in PsA is required (28%). Only 1 respondent (1%) felt GLP-1RA had no role in the management of PsD. Conclusion Clinicians treating PsD agree that excess adiposity promotes higher disease activity and cardiometabolic comorbidity, and lower treatment response, in alignment with the current literature. Interestingly, despite the current interest around GLP-1-RA agents, colleagues were relatively cautious, citing the need for further high-quality evidence for the safety and efficacy of these drugs in PsD. As such, high-quality randomised controlled trials are needed to assess the utility of these medications as an adjunctive treatment in the management of PsD. Disclosure J.C. Williams: None. P. Helliwell: None. D. McGonagle: None. J. Freeston: None. L. Ferguson: None. N. Gullick: None. S.R. Harrison: None. P. Laws: None. G. De Marco: None. J. Packham: None. J. Weddell: None. K. Shams: None. A. Tan: None. W. Tillett: None. S. Zhao: None. N. Sattar: None. S. Siebert: None. H. Marzo-Ortega: None.
Williams et al. (Wed,) studied this question.